158 related articles for article (PubMed ID: 22535159)
1. Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk.
Bestard O; Campistol JM; Morales JM; Sánchez-Fructuoso A; Cabello M; Cabello V; Pallardó LM; Grinyó JM
Nefrologia; 2012 May; 32(3):374-84. PubMed ID: 22535159
[TBL] [Abstract][Full Text] [Related]
2. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
3. [Belatacept, a new original molecule, immunosuppressive, in organ transplantation].
Beaudreuil S; Durrbach A; Kriaa F; Charpentier B
Med Sci (Paris); 2006 Apr; 22(4):354-5. PubMed ID: 16597399
[No Abstract] [Full Text] [Related]
4. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
Vanrenterghem Y; Bresnahan B; Campistol J; Durrbach A; Grinyó J; Neumayer HH; Lang P; Larsen CP; Mancilla-Urrea E; Pestana JM; Block A; Duan T; Glicklich A; Gujrathi S; Vincenti F
Transplantation; 2011 May; 91(9):976-83. PubMed ID: 21372756
[TBL] [Abstract][Full Text] [Related]
5. Belatacept: a new biologic and its role in kidney transplantation.
Su VC; Harrison J; Rogers C; Ensom MH
Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
[TBL] [Abstract][Full Text] [Related]
6. T-cell co-stimulatory blockade in transplantation: two steps forward one step back!
Riella LV; Sayegh MH
Expert Opin Biol Ther; 2013 Nov; 13(11):1557-68. PubMed ID: 24083381
[TBL] [Abstract][Full Text] [Related]
7. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.
Martin ST; Tichy EM; Gabardi S
Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628
[TBL] [Abstract][Full Text] [Related]
8. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
Charpentier B
Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
[TBL] [Abstract][Full Text] [Related]
9. Belatacept: a new era of immunosuppression?
El-Charabaty E; Geara AS; Ting C; El-Sayegh S; Azzi J
Expert Rev Clin Immunol; 2012 Aug; 8(6):527-36. PubMed ID: 22992146
[TBL] [Abstract][Full Text] [Related]
10. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Larsen CP; Grinyó J; Medina-Pestana J; Vanrenterghem Y; Vincenti F; Breshahan B; Campistol JM; Florman S; Rial Mdel C; Kamar N; Block A; Di Russo G; Lin CS; Garg P; Charpentier B
Transplantation; 2010 Dec; 90(12):1528-35. PubMed ID: 21076381
[TBL] [Abstract][Full Text] [Related]
11. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.
Grimbert P; Audard V; Diet C; Matignon M; Plonquet A; Mansour H; Desvaux D; Durrbach A; Cohen JL; Lang P
Nephrol Dial Transplant; 2011 Mar; 26(3):1087-93. PubMed ID: 20667993
[TBL] [Abstract][Full Text] [Related]
12. Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.
Arora S; Tangirala B; Osadchuk L; Sureshkumar KK
Expert Opin Biol Ther; 2012 Jul; 12(7):965-79. PubMed ID: 22564126
[TBL] [Abstract][Full Text] [Related]
13. Costimulation targeting therapies in organ transplantation.
Gandhi AM; Fazli U; Rodina V; Qazi YA
Curr Opin Organ Transplant; 2008 Dec; 13(6):622-6. PubMed ID: 19060553
[TBL] [Abstract][Full Text] [Related]
14. Costimulation blockade with belatacept in renal transplantation.
Vincenti F; Larsen C; Durrbach A; Wekerle T; Nashan B; Blancho G; Lang P; Grinyo J; Halloran PF; Solez K; Hagerty D; Levy E; Zhou W; Natarajan K; Charpentier B;
N Engl J Med; 2005 Aug; 353(8):770-81. PubMed ID: 16120857
[TBL] [Abstract][Full Text] [Related]
15. Rationale for using belatacept in combination with sirolimus.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
[TBL] [Abstract][Full Text] [Related]
16. Belatacept utilization recommendations: an expert position.
Grinyó JM; Budde K; Citterio F; Charpentier B
Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
[TBL] [Abstract][Full Text] [Related]
17. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.
Latek R; Fleener C; Lamian V; Kulbokas E; Davis PM; Suchard SJ; Curran M; Vincenti F; Townsend R
Transplantation; 2009 Mar; 87(6):926-33. PubMed ID: 19300198
[TBL] [Abstract][Full Text] [Related]
18. Co-signals in organ transplantation.
Durrbach A; Francois H; Jacquet A; Beaudreuil S; Charpentier B
Curr Opin Organ Transplant; 2010 Aug; 15(4):474-80. PubMed ID: 20631615
[TBL] [Abstract][Full Text] [Related]
19. Belatacept (Nulojix) for prevention of renal transplant rejection.
Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):98-9. PubMed ID: 22173428
[No Abstract] [Full Text] [Related]
20. Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker.
Poirier N; Blancho G; Vanhove B
Immunotherapy; 2010 Sep; 2(5):625-36. PubMed ID: 20874646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
